QBIO Accelerating Biomedical Technologies from Incubation to Monetization Investor Presentation - QBioMed
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
Accelerating Biomedical Technologies
from Incubation to Monetization
Investor
M AY / J U N E
2 0 1 9 Presentation
QBIO
Forward Looking Statements
This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as
amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which are not purely historical
are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These
forward-looking statements generally can be identified by phrases such as Q BioMed, Inc. (“QBIO”) or its management "believes," "expects,"
"anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar importance. Such forward-looking statements include,
among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in
these forward-looking statements which are made as of the date of this presentation, and we assume no obligation to update any forward-
looking statements. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and
uncertainties associated with our business, which include the risk factors disclosed in our public filings.
Although we believe that any beliefs, plans, expectations and intentions contained in this presentation are reasonable, there can be no
assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should review all of the information set
forth herein, and should also understand the risk factors and the inherent uncertainties associated with new business opportunities and
development stage. Any use of this information for any purpose other than in connection with the consideration of an investment in Q BioMed
Inc. may subject the user to criminal and civil liability.
This presentation does not constitute an offer to sell any securities or the solicitation of an offer to sell any securities by Q BioMed Inc.
2019-06-06 Copyright © 2019 Q BioMed Inc. 2
Rapid Biotech Growth Has
Created an Opportunity
Q BioMed leverages this opportunity by accessing undiscovered, undervalued biomedical
technologies for investment, acceleration and monetization
2019-06-06 Copyright © 2019 Q BioMed Inc. 3
The Q BioMed Business Model
IDENTIFY Preliminary scientific and commercial criteria review. Determining
Criteria match and fit management's expectations and flexibility moves the asset to the next step.
A N A LY Z E Due diligence is combined with a validation of management's development
Asset and development plan and capital requirements.
INVEST Performance-based capital is deployed to meet specific and mutually-agreed
Capital attached to goals goals in each stage.
Additional resources are infused to move the asset through development
A C C E L E R AT E
Increase investment and ownership stages and to a value-creating inflection point.
MONETIZE Assets can be sold, licensed, joint-ventured or operated as cash flow positive
Operate, partner, license, IPO or sell product lines. QBIO's goal is to maximize value for its shareholders.
2019-06-06 Copyright © 2019 Q BioMed Inc. 4
Management Team
Denis Corin William Rosenstadt Dr. Rick Panicucci Ari Jatwes David Laskow-Pooley Robert Derham
Chief Executive Officer Chief Legal Officer Pharmaceutical Development Business Development Analyst VP Product Development VP Orphan Products
General Counsel
Chairman of the Board
Director Director
Advisory Board
Dr. Helen Tager- Dr. Susan Quaggin George Nikopoulos Dr. Amy Ripka Dr Nafeez Zawahir Dr Raj Apte
Flusberg CSO, Manin Research CEO, Mannin Research Medicinal Chemistry Medical Advisor Washington University -
Professor of Director, Feinberg Cardiovascular and BioChemistry and Molecular Genetics. Market Research Ophthalmology
Psychology Renal Research Institute NIH Post Doc fellow. Columbia University and Methodist Paul A. Cibis Distinguished Professor
Chief of Nephrology and Hypertension Hopital. of Ophthalmology and Visual
Director of the Center in the Department of Medicine CME Reviewer WebMD Medscape. Sciences
for Autism Research Charles H. Mayo, MD, Professor Large Pharma Consultant
Excellence Professor of Medicine (Nephrology and
Boston University Hypertension)
Northwestern
Kristin Keller Dr. John Jay Gargus Dr Jin Jeng
Agency – Professor, Physiology & Biophysics Recombinant Protein
Commercialization Director of Center for Autism Ophthalmology
Lead Research and Translation (UCI CART) Northwestern Feinberg School of
Medicine
Professor, Pediatrics Assistant Professor of Medicine
UC Irvine School of Medicine (Nephrology and Hypertension)
2019-06-06 Copyright © 2019 Q BioMed Inc. 5
Our Growing Portfolio of High-Value Assets
ONCOLOGY OPHTHALMOLOGY RARE ORPHAN DISEASES VASCULAR DISEASES
MAN-01 MAN-03
MAN-11 MAN-04
™ GDF15
2019-06-06 Copyright © 2019 Q BioMed Inc. 6
A Growing Pipeline Mitigates Risk and
Drives Shareholder Value
PHASE PHASE PHASE
DRUG CANDIDATE PRECLINICAL APPROVAL COMMERCIALIZATION
1 2 3
Radiopharmaceutical for metastatic cancer bone pain (Branded)
Radiopharmaceutical for metastatic cancer bone pain (Generic)
Rare pediatric non-verbal Autism
Spectrum Disorder (Pre-IND 505b2)
GDF15 Biomarker for glaucoma
Chemotherapeutic for
liver cancer
MAN-01 Eye drops for glaucoma
MAN-11 Biologic for glaucoma
MAN-03 Acute kidney injury
MAN-04 Cardiovascular Diseases
2019-06-06 Copyright © 2019 Q BioMed Inc. 7
Radio-Pharmaceutical: Metastron™ / Strontium Chloride 89 Injection
Condition: Bone Pain - Cancer Metastases
Addressable Market: ~110,000 yearly
Technology Partner: BioNucleonics Inc and GE Healthcare
Commercializing – Awaiting FDA Approval of
Stage:
Manufacturing Facility
THE CONDITION:
PAINFUL BONE METASTESES from Prostate
and Breast Cancer
Prevalence
450,000* new breast and prostate cases are recorded each year
1 in 3 people will develop bone metastases from the spread of breast and
prostate cancer
In a 2012 publication it was estimated that over 280,000 people in US and
2,000,000 worldwide to be living with the painful condition
*Source: American Cancer Society, 2016
Current Standards of Care
Pain is the most common sign of bone cancer, and may become more
noticeable as the tumor grows.
Bone pain can cause a dull or deep ache in a bone or bone region (e.g., back,
pelvis, legs, ribs, arms).
Treatment options include:
Pain Medications: Radiation Therapy
Opioids Radiopharmaceuticals
Orthopedic Procedures
Sr89 is NON-NARCOTIC and can mitigate opioid use
2019-06-06 Copyright © 2019 Q BioMed Inc. 9
NON-OPIOID PAIN RELIEF from Metastatic Cancer • FDA-approved non-opioid for painful metastases • Medicare and Health Care Reimbursed • Broadly Indicated to relieve bone pain from skeletal metastases from breast, lung prostate and other cancers • Simultaneously targets all sites of metastatic bone pain • ONE DOSE - Effective in 80% of patients and lasts average of 6 months • Can be used with opioid based drugs and cancer therapeutics • Studies demonstrated a prolonged progression-free result and overall survival with acceptable toxicity • Ph2 Trial showed 9-month survival benefit (vs 2 months in Blockbuster competitor) – A Planned PH4 trial to confirm this will exponentially increase potential revenue 2019-06-06 Copyright © 2019 Q BioMed Inc. 10
METASTESES SPREAD TO MULTIPLE SITES
The Challenge of Bone Mets How Our Drug Works
Bone Met
(Tumor)
Multiple skeletal metastases cannot be treated with External Beam Radiation • Imitates calcium in vivo and rapidly localizes to
proliferating bone
• 85% of breast and prostate cancer patients develop Bone Mets
• Absorbs at a rate 10-fold higher in prostatic bone
• 2 million people worldwide suffering and under treated
metastases than in healthy bone
• Few treatment option for multiple skeletal metastases
• Retained in metastatic lesions enabling a larger radiation
dose to metastases for up to 6 months
2019-06-06 Copyright © 2019 Q BioMed Inc. 11METASTRON™ Effectively Palliates
Cancer Bone Pain
Study Patients (N) Dose Cancer Pain Relief
Fuster 2000 40 4 mCi Breast 92%
Kraeber-Bodere 2000 94 4 mCi Prostate 78%
Turner 2001 93 4 mCi Prostate 63%
Ashayeri 2002 27 4 mCi Prostate and Breast 81%
Gunawardana 2004 13 4 mCi Prostate 57%
Liepe 2007 15 4 mCi Prostate and Breast 72%
2019-06-06 Copyright © 2019 Q BioMed Inc. 12METASTRON™ Offers Lasting Pain Relief
Study Patients (N) Dose Cancer Pain Relief Median duration
Fuster 2000 40 4 mCi Breast 92% 120 days
Moderate bone involvement: 5 mos
Kraeber-Bodere 2000 94 4 mCi Prostate 78%
Extensive bone involvement: 2 mos
Gunawardana 2004 13 4 mCi Prostate 57% 56 days
2019-06-06 Copyright © 2019 Q BioMed Inc. 13METASTRON™ Improves Quality of Life • Treatment with METASTRON™ has led to a significant improvement in QoL for patients with metastatic bone disease associated with breast and castration-resistant prostate cancer • Treatment with METASTRON™ has been demonstrated to reduce or eliminate need for analgesics 2019-06-06 Copyright © 2019 Q BioMed Inc. 14
• A decrease of >50% in serum PSAV was observed
in 37% of patients with hormone-refractory
prostate cancer after treatment with
METASTRON™ 6
• In a multicenter, RCT involving 126 patients
with mCRPC, all of whom received external
METASTRON™ May beam radiotherapy, additional treatment with
METASTRON™ delayed disease progression
Slow Metastatic [Porter_1993]
Disease • Many patients show a reduced intensity of hot
spots on bone scan compared with
Progression pretreatment images.11,16 suggesting a possible
tumoricidal effect from METASTRON™.
• Case reports describe regression of osteoblastic
and osteolytic bone metastases in patients with
breast cancer and hepatocellular carcinoma
after treatment with METASTRON™ 16,17
2019-06-06 Copyright © 2019 Q BioMed Inc. 15METASTRON™ has been shown to extend clinical progression free survival (CPFS). • In the recent TRAPEZE randomized controlled trial of the clinical effectiveness and cost- effectiveness of chemotherapy with zoledronic acid (ZA), METASTRON, or both in men with bony metastatic castration- refractory prostate cancer, METASTRON was shown to improve CPFS, while ZA did not. • The METASTRON group was also associated with lower use of radiotherapies, abiraterone, ZA and METASTRON as concomitant medications, as well as fewer inpatient days, outpatient appointments and GP visits. 2019-06-06 Copyright © 2019 Q BioMed Inc. 16
METASTRON™: Increasing Evidence of an Overall Survival (OS) Benefit
Metastron OS Data • In one study of 103 patients with mCRPC
50 randomized to doxorubicin alone or
doxorubicin with METASTRON, a median
45
overall survival of 16.8 months and 27.7
40
months was seen, respectively 9
35
30 • In an earlier trial examining METASTRON vs
25
placebo in mPC and mCPRC patients, Buchali
et al reported a survival rate 2 years after
20
the start of treatment of 46% in METASTRON
15 and 4% in placebo groups. 19
10
5
• In these clinical studies, differences in
METASTRON dosing, baseline patient
0
Trapeze Study Buchali et al Kuroda PSA Tu et al Combo characteristics, and prior treatments are
Metaston Other/Placebo
likely to affect reported patient outcomes
Future randomized, placebo-controlled studies may confirm the effect of METASTRON on overall
survival
2019-06-06 Copyright © 2019 Q BioMed Inc. 17METASTRON™ Investment Thesis
FDA approved – Palliation
Global Market Authorizations (22 countries)
Medicare Reimbursed
Commercially available for SALE in 2019 (Est FDA US
Facility Approval)
BLUE SKY
Irradiates tumors and has been used in combination
with CHEMOTHERAPY
Increased survival by 9 months - MD
Anderson/Lancet
https://www.ncbi.nlm.nih.gov/pubmed/11210994
Phase 4 Clinical Program to amend label to
THERAPEUTIC DRUG
Potential Revenue $200M+ in Yr1 post Clinical trial
(Current Competitor $800M/yr.)
2019-06-06 Copyright © 2019 Q BioMed Inc. 18Our Competitors, Revenue Model and Launch Plan
Treatment Comparative Analysis
Characteristics Opioids Metastron (Sr89)
Ramp Up to
Action On the central nervous system Reduction of tumor mass
Commercialization
Pain Palliation Begins Within 15 to 20 min 1 to 2 weeks after administration Material Procurement
Pain Palliation Last 3 – 4 Hours 3 to 12 Months (Average: C O M P L E T E D
6 months)
Side Effects Confusion, depression, sleepiness, Transient mild myelo-suppression Manufacturing
nausea, constipation, vomiting. Gradual between 4 to 8 weeks after I N P R O C E S S
resistance, creating need of higher doses administration, with complete recovery
within 3 months
Need of Hospitalization Requires regular administration and No. Production Validation
nursing care I N P R O C E S S
“[Opioids] can lead to a lot of side effects because “I thought [strontium] was the coolest thing. Great
then the patient is completely lethargic…like being responses. The pain dramatically improved in the
in a fog.” – Oncology Nurse breast patients that had bone metastases.”
– Radiation Oncologist
Distribution
I N P R O C E S S
Potential Revenue Targets
Indication Market Revenue
Marketing
Cancer Bone Pain 3000 – 6000 Doses @ $10000/Dose FY2021 Approx.: $25,000,0000 - $50M I N P R O C E S S
1500-3000 Patients
Future Possibility 30 – 60,000 Doses @ $10,000/Dose FY 2023 Approx.: $250M – $500,000,000
Therapeutic Bone Cancer 5000 – 10000 Patients
5-10% of the Patient Population Launch and Sales in 2019
2019-06-06 Copyright © 2019 Q BioMed Inc. 19METASTRON™ Is Commercially Ready for U.S. Sales
and Distribution
• Commercial team onboarded
• Commercial infrastructure is in set-up mode:
• Medical Information/Pharmacovigilance partner
• Government contracting partner
• Contract and telesales
• Distribution partner identified - capabilities include: warehousing/inventory
management; invoicing; customer service/ordering
• Features a National Accounts sales team that calls on all major and
independent nuclear pharmacies
• Distributes in all 50 states
• Reimbursement landscape and pricing strategy completed
• Scientific platform completed
• Creative advertising campaign and sales materials in development
Copyright © 2019 Q BioMed Inc. 2019-06-06 20Efforts to Maximize Uptake of METASTRON™
Establish scientific relevance and credibility
• Create a METASTRON Key Opinion Leader (KOL) Advisory Board
• Members will include key academic faculty, high volume treaters and METASTRON loyalists
• Members will assist in developing phase IV clinical development plan, creation of
publications, and deliver symposia at national conferences
• Generate meta-analysis publication validating efficacy by Q4’19
Generate awareness and demand for METASTRON
• Create awareness that METASTRON is “coming soon” through a teaser campaign in Q3-4’19
• Target primary customer base via digital channels and congresses
• Deepen awareness and stimulate prescribing with brand launch campaign and sales efforts at
manufacturing approval
• Campaign communications and sales will reach customers through targeted digital Greatest Unmet Need? Awareness!
“I used [strontium] a lot when it first came out. I loved it. And
marketing, telesales and focused commercial team sales calls then Quadramet came out and they had the rep would
constantly remind us…and switched over to Quadramet. Same
• Extend reach and influence via robust scientific congress and speaker program results. I didn’t see anything different. I was just reminded
about it.”
– Radiation Oncologist
Copyright © 2019 Q BioMed Inc. 2019-06-06 21-001
Pharmaceutical: QBM-001 Sprinkle Formulation
Rare Pediatric Minimally Verbal Autism
Condition:
Disorder
50,000 cases worldwide
Addressable Market:
15,000 in US alone
Technology Partner: ASDERA, LLC
Stage: Pre-IND 505(b)2THE CONDITION:
RARE PEDIATRIC MINIMALLY VERBAL DISORDER-
Autism Spectrum Disorder
Prevalence
Among the >60,000 US children who develop Autism Spectrum Disorders (ASD)
every year, 20,000 become minimally or nonverbal and will have to rely
on assisted living for the rest of their life. Of the estimated 20,000 diagnoses a
year in the US, QBM-001 should be able to treat about 15,000.
The lifetime cost of care is estimated at $5-10 M/person.
Current cost to US healthcare is $200B per year.
No treatment with lasting effects on how children develop
Fundamental defects in social reciprocity and communication
Repetitive and stereotypical behaviors
Current Medications* and 2016 Sales
Name Condition 2016 Sales
Abilify® Irritability $2.0 B + (off Patent)
Vyvanse® ADHD $2.0 B
Risperdal® Aggression $3.0 B
* These medications do not treat the condition, rather, they are psychotherapeutic interventions that ameliorate
temperament/mood only.
2019-06-06 Copyright © 2019 Q BioMed Inc. 23REGULATES FAULTY ION-CHANNELS to Allow Language Development
NEURON PRUNING • 8-12 months – detection of early symptoms
Children with ASD loose the ability to learn language once their
language-specific neurons are naturally pruned • 12-15 months – language regression
• Brain density in cortex (speech region) declines after 24
• Due to pruning, fMRI shows “patches of disorganization” seen in the
cortex of the brain of non-verbal children older than 24 months
HOW IT WORKS
Diagnosis
• ASD diagnosis or high-risk group with developmental delay
1 Mo. 6 Mos. 2 Yrs. 4 Yrs. 6 Yrs. • Tested for elevated serum markers
• Genetically tested to exclude diseases that QBM-001 cannot treat
At 2 years of age, the brain is
actively developing neuron
connections at the peak of the QBM-001 acts as an allosteric regulator of faulty membrane channels in
leaning process. the brain that are known to cause migraines and/or seizures, thus
allowing QBM-001 to potentially alleviate the condition and allow
Around the age 2, the brain more actively prunes toddlers to actively develop language and avoid life-long speech and
(eliminates) neurons that are not in use.
intellectual disability of being nonverbal.
When language development is impeded in this
subset of ASD children, their language neurons do
not activate and are targeted for pruning by the Results from two independent studies (Wittkowski, 2014) showed lack of language associated
brain. with: poorly regulated membrane channels (excitation/inhibition imbalance) and included
known ‘migraine’ genes.
If you do not use it, you lose it.
2019-06-06 Copyright © 2019 Q BioMed Inc. 24PRICE VS. COST:
The Hard Facts and Emotional TRUTH
There are NO drugs currently available to ameliorate this condition.
Orphan drugs (less than 200k patients) average price $100,000 per
year (EvaluatePharma).
The alternative – estimated at $10m in direct costs and $10M in lost
productivity due to lifetime assisted living, supplemental healthcare
costs, and lost productivity of family members.
Not measuring the severe emotional strain of never talking to your
child.
This pediatric minimally verbal autism disorder, where children
lose or don’t develop and manifest with ASD symptoms is rare and
limited to approximately 20,000 children a year in the US and about
the same in Europe, of which QBM-001 should be able to treat
15,000-18,000 for 2-3 years.
MARKET POTENTIAL
United States: 20,000 patients per year @ $100,000 - $2B
Europe and ROW: 30,000 Patients per year @ 100,000 - $3B
2019-06-06 Copyright © 2019 Q BioMed Inc. 25UTTROSIDE-B
Pharmaceutical: UTTROSIDE-B
Condition: Liver Cancer
Addressable Market: 700,000 Aprx: 40,000/year in US
Technology Partner: Oklahoma Medical Research Foundation
Stage: Preclinical - Orphan DiseaseTHE CONDITION: LIVER CANCER The 10th Most Common Cancer Prevalence • More than 700,000 people worldwide are diagnosed each year • Estimated 39,230 adults in the United States will be diagnosed every year • Numbers have tripled since 1980 • Poor 1-year survival rate • 18% 5yr Survival Current Standards of Care RADIATION SURGICAL High-energy x-rays or other particles destroy cancer Hepatectomy or liver transplantation cells DRUG TREATMENT CHEMOTHERAPY Tryosine kinase inhibitor antineoplastic agent, Radiofrequency ablation (RFA) and microwave therapy Nexavar™ THERMAL Percutaneous ethanol injection 2019-06-06 Copyright © 2019 Q BioMed Inc. 27
Chemotherapy IN VITRO
IC-50 of Sorafenib is 5.8 uM in Hep G2 while Uttroside-B is 500
Uttroside-B appears to affect phosphorylated JNK (pro survival
signaling) and capcase activity (apoptosis in liver cancer) 6000
A natural compound 5800
4000
Fractionated Saponin derived from S. nigrum
Small molecule 2000 500
Steroid Glycoside 0
Uttrocide-B Sorafenib
Uttroside B increases the cytotoxicity of a variety of liver
cancer cell types
• Up to 10x more potent than Sorafenib in pre clinical studies
IN VIVO
HepG2 Injected Into Mice Then Treated with 10mg of Uttroside-B for
Cytotoxicity specific to cancerous liver cells One Month
Provisional patent filed
200
Molecule syntheses completion June 2019
150
IND Ready Q4 2019
100
Sorafenib Tosylate (Nexavar™) is currently the only FDA- approved
50
drug for the first line treatment of liver cancer.
0
2017 sales exceed $1B Week 1 Week 2 Week 3 Week 4
Control Uttrocide B
2019-06-06 Copyright © 2019 Q BioMed Inc. 28MAN-01
Pharmaceutical: MAN-01 Topical Drops
Condition: Primary Open-Angle Glaucoma
Addressable Market: 80 million patients worldwide
Technology Partner: Mannin Research Inc.
Stage: PreclinicalTHE CONDITION:
ELEVATED INTRAOCULAR
PRESSURE (IOP)
Primary Open-Angle Glaucoma
Prevalence Current Standards of Care
• 60 million patients worldwide • Pharmaceuticals
• 8 million with bilateral • Laser Surgery
blindness • Traditional surgery
Patient Pain Points
• Ineffective current standards of care
• Compliance: Between 20% and 66% of patients do not use their medication
as prescribed
• Adherence: Fewer than 25% of patients use their eye drops continuously for
12 months
Physician Paint Points
• Intra-ocular pressure (IOP) is a risk factor but not an effective measuring
tool
• Increase compliance and adherence
Market Pain Points
• Market is seeking for new & better treatments (new MOAs) for glaucoma
drugs
• Innovation in drug design and improve drug delivery and availability
2019-06-06 Copyright © 2019 Q BioMed Inc. 30P.O.C Data Shows Novel Relationship Between Angiopoietin-Tie2 and Elevated IOP While control eyes (A, C, F, and I) appeared normal, 8- to 9-week-old A1A2- (B, D, G, and J) and Tie2-cKO (E, H, and K) mice exhibited anterior chamber enlargement due to increased IOP (L). Optomotor response tests (M) showed impaired vision in mutant animals. Scale bars: 1 mm (F, G, and H) and 500 μm (I, J, and K). **P < 0.01 and ***P < 0.001 by Student’s 2-tailed t test. Error bars indicate SEM. No response (NR) indicates an optomotor response of less than 0.042 cycles per degree. J Clin Invest DOI: 10.1172/JCI77162 2019-06-06 Copyright © 2019 Q BioMed Inc. 31
Pathway Validated by Independent Researchers
2019-06-06 Copyright © 2019 Q BioMed Inc. 32Lead Optimization Screening Program
CHEMICAL SYNTHESIS PROJECTED PHASE I
VE-PTP INHIBITION (IC50) GLAUCOMA CLINICAL TRIAL
PERMEABILITY STUDIES
SOLUBILITY STUDIES
Q4 2019 / Q1 2020
IN VITRO TIE2 ACTIVATION ASSAY
IN VIVO TIE2 ACTIVATION ASSAY
PHARMACODYNAMICS
PROJECTED LEAD CANDIDATE
(EX-VIVO EYE OUTFLOW ASSAY)
SELECTION
OCULAR PENETRATION
PHARMACOKINETICS Q2 2019
FULL RABBIT OCULAR PK
DISEASE MODELS Data Available* *Access to Data Available under CDA
2019-06-06 COPYRIGHT © 2019 Q BIOMED INC. 33General Synthetic Strategy
GENERATED OVER 400+ COMPOUNDS
54% OF COMPOUNDS HAVE IC50Novel Mechanism of Action with
Potential to Treat Other Diseases
MAN-01: Small Molecule for Glaucoma
• First-in-class drug with novel MOA – Angiopoietin-Tie2
signaling pathway
• Addresses need for innovation
• Mechanism targets the critical Schlemm’s Canal
• The Schlemms Canal is responsible for 70%-90% of fluid
drainage in the eye
• Primary indication for Primary Open-Angle Glaucoma
• Additional indications may include:
• Acute Kidney Injury
• Cardiovascular Disease
• Infectious Diseases
Treatment for Acute Kidney Injury, which contributes to high morbidity and mortality rate in a wide range of
MAN-03 Acute Kidney Injury injuries, including common clinical care settings such as coronary artery bypass surgery, contrast-induced
nephropathy and sickle cell nephropathy.
Treatment with our pharmacologic small molecule will likely protect the lungs and slow disease progression in
MAN-04 Cardiovascular Diseases patients with Pulmonary Artery Hypertension. Treatment may also provide protection to the myocardium in
patients with Congestive Heart Failure and Myocardial Ischemia.
2019-06-06 Copyright © 2019 Q BioMed Inc. 35GDF15
Biomarker & Companion Diagnostic: Growth Differentiation Factor 15 (GDF15)
Condition: Monitoring Glaucomatous Neurodegeneration
Addressable Market: 80 million glaucoma patients worldwide
Technology Partner: Washington University in St. Louis
Stage: Clinical using GDF15 as Biomarker;
Preclinical Development of Companion
Diagnostic KitGDF-15: Novel Biomarker for Glaucoma
• Growth Differentiation Factor 15 (GDF15) is a member of the
transforming growth factor (TGF-β) superfamily and was
recently identified as a promising biomarker for glaucoma.
• Discovered to be a biomarker for glaucoma by performing array
analysis to identify chemokines, growth factors, TGFβ family
members and other ligands whose expression increased in the
optic nerve crush model of glaucoma but not in endotoxin-
induced uveitis or light-induced retinal degeneration models.
• Validated in both rat models of glaucoma and human patients
and its expression correlated with disease severity.
• GDF15 represents an attractive biomarker for glaucoma with
distinct advantages (i.e., early detection) over conventional
clinical tests and has the potential to be a first-in-class
diagnostic test.
Patent Application: 62/289,030 “GDF15 in glaucoma and methods of use thereof”
2019-06-06 Copyright © 2019 Q BioMed Inc. 37MONITORING GLAUCOMATOUS NEURODEGENERATION
• Accurate monitoring for evidence of disease progression is vital to preserve visual function of
glaucoma patients
• Desired goal of any glaucoma therapeutic intervention is neuroprotection, leading to survival of
retinal ganglion cells (RGCs)
• Physicians currently have only surrogate measures of glaucomatous neurodegeneration
• No single examination or diagnostic test is able to accurately predict disease progression
Tonometry (IOP measurement) Optical Coherence Examination of the Perimetry
Tomography (OCT) Optic Nerve (Visual Field Testing)
Pros: Pros: Pros: Pros:
• Essential for assessing the • Automated • Can be performed routinely in a • Direct measurement of
effectiveness of IOP lowering • Objectively quantifiable clinical seeing glaucoma in the patient’s
treatment • Can be recorded by a visual function
photograph
Cons: Cons: Cons: Cons:
• Values are affected by central • No reliable normative • Subjective (observer designates • Subjective (patients
corneal thickness database the rim margin of the cup) respond when the light is
• No direct correlation with projected)
glaucomatous neurodegeneration
2019-06-06 Copyright © 2019 Q BioMed Inc. 38Capital Markets Overview and
Management OutlookQ BioMed in the NEWS
Capital Markets Q BioMed Inc Announces Acquisition of Cancer Pain
Drug Metastron™ from GE Healthcare
As of Dec 4, 2018
Strategic Acquisition Gives Company Ownership of
Shares Outstanding 14,200,000 Market Cap $28.5 M Brand Name Drug and Related Market
Authorizations in 22 Countries in Which Metastron™
Warrants Ave Price
4,8M $3.50 is Already Registered and Approved for Sale
November 2018
Inside Ownership 25% Avg. Volume 50,000
30 day
Float ~ 10,000,000 Year end November 30 Q BioMed Provides Important Update on QBM001
Developmental Drug Targeting a Non-Verbal and
3-Month Trading History Price $ 1.70 Minimally Verbal Patient Subset on the Autism
Spectrum
Company Further Develops Its Autistic Spectrum
Disorder (ASD) Drug Technology and Expects
Several Development Partnerships In Anticipation of
Clinical Program in 2019.
OCTOBER 2018
Q BioMed Announces Closing of $4M Financing
QBIO
Biomed Inc. Announces Dr. Rajendra Apte Joins
Advisory Board
Distinguished Ophthalmology Specialist Brings
Wealth of Experience
SEPTEMBER 2018
2019-06-06 Copyright © 2019 Q BioMed Inc. 40What to expect from us Metastron™ (Strontium Chloride 89) - FDA-approved Manufacturing underway - Awaiting FDA review of contract facility Revenue generation expected in 2H 2019 Ph4 Post Marketing Study for Expanded Therapeutic Label Q4 20 Revenue in 2019 QBM-001 Pre-IND Filing, Orphan Drug Filing 2H 2019 1.5year Pivotal Clinical Trial 1H 2020 Uttroside-B – Liver Cancer Complete pre-clinical and Prepare IND 2H 2019 Proof of Concept Studies H1 2020 File IND Q4 2019 MAN-01 Complete Molecule Optimization (Eye Drop) Initiate Pre-IND Studies 2H2019 – Clinical Trial IND Q4 2019 Additional Indications Formalized 2019 Pharma Partnership opportunities QBIO Potential up-list to national exchange in H2 2019 2019-06-06 Copyright © 2019 Q BioMed Inc. 41
Accelerating Biomedical Technologies
from Incubation to Monetization
Corporate
366 Madison Avenue
New York, NY 10222
USA
+1 (888) 357-2435
Executive & Investors
QBIO
Denis Corin, CEO
dcorin@qbiomed.com
qbiomed.comYou can also read
